focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,110.00
Bid: 12,086.00
Ask: 12,088.00
Change: -56.00 (-0.46%)
Spread: 2.00 (0.017%)
Open: 12,186.00
High: 12,198.00
Low: 12,068.00
Prev. Close: 12,166.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Africa proves rocky terrain for Russian and Chinese vaccines

Fri, 12th Mar 2021 06:00

* Western powers under fire for vaccine hoarding

* Moscow, Beijing pledge to help bring shots to Africa

* Donations relatively small, commercial deals rare and
costly

* Some governments concerned by lack of data

* For a graphic: https://tmsnrt.rs/3rCOEDP

By Joe Bavier and David Lewis

JOHANNESBURG, March 12 (Reuters) - Russia and China are
racing to plug the COVID-19 vaccine gap in Africa, hoping to
cement their influence on a continent where many countries have
yet to administer a single shot.

But, so far, vaccine donations from Beijing and Moscow have
been small, the commercial deals they offer are costly, and some
African governments are wary about a lack of data.

As rich countries ramp up their inoculation drives, Africa,
without the resources to pre-order Pfizer, AstraZeneca
, Moderna and Johnson & Johnson
vaccines, is being left behind.

With Western nations facing criticism for hoarding supplies,
flooding Africa with life-saving shots would be a soft-power
coup for Russia and China.

Moscow has offered 300 million doses with financing to an
African Union (AU) purchasing scheme.

Beijing has pledged nearly a quarter of all its vaccine
donations to Africa, according to data compiled by Bridge
Consulting, a Beijing-based health sector advisory.

"This is a vivid manifestation of China-Africa friendship,"
China's foreign ministry told Reuters.

"Africa is one of the key markets for Sputnik V," said the
Russian Direct Investment Fund (RDIF), the sovereign wealth fund
marketing its Sputnik V vaccine abroad.

French President Emmanuel Macron says Europe and the United
States risk losing influence in Africa over the issue.

However, John Nkengasong, head of the Africa Centres for
Disease Control and Prevention, cautioned against "vaccine
diplomacy", saying powers must not use token allocations to
curry political influence.

"Africa will refuse to be that playing ground where we use
COVID as a tool to manage relationships," he said on a webinar
hosted by the Atlantic Council think tank in late February.

"It becomes like you're trying to sprinkle water on a very
hot day on children ... Then you can tick the box that you did
that," he said. "That's not what we are after as a continent."

While other developing regions have turned to Russia or
China, in Africa their engagement has translated into few shots
in arms.

Africa has received around 3.15 million shots from China -
or less than 4% of its vaccine exports - Bridge Consulting data
showed.

"The numbers of vaccines China is donating are not going to
move the needle in any of these countries. But it's as much
about the optics," said Eric Olander, co-founder of The
China-Africa Project.

Russia has shipped a total of around 100,000 vaccine doses
to Algeria, Tunisia and Guinea.

The global vaccine sharing scheme COVAX, meanwhile,
delivered nearly 15 million shots to 22 African countries in its
first 10 days.

The facility co-led by the World Health Organization, GAVI
and others aims to ship 35 million doses to Africa by the end of
the month and 720 million by the end of 2021.

That will still only be enough to inoculate those at
greatest risk.

DATA DEFICIT

China's leading vaccines - from the China National
Pharmaceutical Group (Sinopharm) and Sinovac - are not yet
approved for emergency use by the WHO. Neither is Russia's
Sputnik V vaccine.

China offered South Africa - the African nation hardest hit
by the pandemic - 2 million shots, its health minister said.

But a government official involved in procurement told
Reuters the lack of trial data meant Chinese vaccines were not
being seriously considered for now. Sputnik V was also relegated
to a second tier of vaccines South Africa says need more study,
according to the health ministry.

Even some countries that accepted donations have shied away
from purchases.

Uganda considered buying Chinese vaccines but is focused on
COVAX due to their cost and the availability of data, said
Ombeva Malande, director of the East Africa Centre for Vaccines
and Immunization, which advised the government. Kenya is taking
a similar line, he said.

Diana Atwine, permanent secretary in Uganda's health
ministry, said authorities would consider affordable vaccines
approved by the WHO.

The head of Kenya's vaccine task force confirmed it was not
in talks to procure Chinese vaccines, and health ministry plans
do not include Russian vaccines.

DOLLARS AND DOSES

While COVAX shots are free for most African nations,
countries doing commercial deals are paying a premium.

Senegal paid $20 a shot for 200,000 doses of Sinopharm, a
two-shot vaccine.

"The worst thing that could happen now is for countries to
not start vaccinating," said Tandakha Ndiaye Dieye, a member of
Senegal's vaccine advisory group, explaining the decision.

By comparison, India's Serum Institute is selling
AstraZeneca shots it manufactures for $3. The Indian government
has also donated over a half million of those shots to eight
African countries, according to a Reuters tally.

Beijing has so far not announced financing packages that
would make vaccine deals more affordable in Africa.

At around $10 per dose, Sputnik V is cheaper, and RDIF told
Reuters it would be even more competitive if subsidised via
COVAX.

RDIF said it was in "advanced negotiations" with the WHO to
be included in COVAX and could offer a one-shot version to
reduce the cost. A spokesperson for GAVI, the global vaccine
alliance helping lead COVAX, said all vaccines would be
considered but they first needed approval from the WHO or
another stringent regulatory authority.

RDIF said some deliveries of the Sputnik V doses offered via
the AU plan could start in May.

A senior AU diplomat told Reuters that talks were taking
place but no agreement had been reached. No details have been
announced about the finance package. RDIF did not respond to
Reuters questions about the potential deal.

Both China and Russia must increase production if they hope
to become major global vaccine suppliers. For Moscow, exporting
shots is politically sensitive when its own population still
needs vaccinating.

"I'm not worried about whether Russia's going to be able to
deliver the doses," said W. Gyude Moore of the Center for Global
Development, a Washington think tank.

"I'm worried about how African countries are going to pay
for them ... COVAX is just not going to be enough."

(Additional reporting by Duncan Muriri in Nairobi, Elias
Biryabarema in Kampala, Alexander Winning in Johannesburg,
Polina Ivanova and Polina Nikolskaya in Moscow, Bate Felix in
Dakar, Roxanne Liu in Beijing, Giulia Paravicini in Addis Ababa
and Kate Kelland in London; Editing by Giles Elgood)

More News
11 Apr 2024 08:54

LONDON MARKET OPEN: European markets mixed ahead of ECB decision

(Alliance News) - European equities lacked direction early Thursday morning, ahead of an interest rate decision from the European Central Bank this afternoon.

Read more
11 Apr 2024 07:49

LONDON BRIEFING: Astra promises dividend hike; Darktrace ups guidance

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye the latest interest rate decision from the European Central Bank, a day after a hotter-than-expected US inflation reading.

Read more
11 Apr 2024 07:20

AstraZeneca to hike 2024 dividend by 7%

(Sharecast News) - Biopharma giant AstraZeneca has announced that it will increase its annual dividend by 7%, which the board said demonstrates its confidence in the company's performance and cash generation.

Read more
8 Apr 2024 08:36

TOP NEWS: AstraZeneca hails neurological data for Ultomiris, Soliris

(Alliance News) - AstraZeneca PLC on Monday said long-term data in generalised myasthenia gravis will underscore the "vital role" of its Ultomiris and Soliris antibodies in the treatment landscape.

Read more
8 Apr 2024 07:43

LONDON BRIEFING: Astra hails neurology data; CVS flags cyberattack

(Alliance News) - London's FTSE 100 is called to open a touch higher on Monday, ahead of an interest rate decision in the eurozone and a US inflation reading later in the week.

Read more
8 Apr 2024 07:02

AstraZeneca's Enhurtu cancer gets US green light for adult patients

(Sharecast News) - AstraZeneca and Daiichi Sankyo's Enhertu cancer drug has been approved in the US for adult patients with unresectable or metastatic solid tumours who have received prior systemic treatment and have no satisfactory alternative options.

Read more
8 Apr 2024 06:53

TOP NEWS: AstraZeneca's, Daiichi's Enhertu receives US FDA approval

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Saturday announced that the US Food & Drug Administration has approved their cancer drug conjugate for patients with metastatic HER2-positive solid tumours.

Read more
5 Apr 2024 09:42

AstraZeneca makes "breakthrough" in treating small cell lung cancer

(Alliance News) - AstraZeneca PLC on Friday reported positive results relating to its Imfinzi cancer treatment in phase III trials.

Read more
5 Apr 2024 07:50

LONDON BRIEFING: Shell to book USD600 million first-quarter write-off

(Alliance News) - London's FTSE 100 is called to open lower on Friday, with hawkish remarks from Federal Reserve policymakers and fears of ratcheting Middle East tensions giving investors little to cheer about ahead of the latest US jobs data.

Read more
5 Apr 2024 07:23

AstraZeneca announces positive lung cancer treatment trial results

(Sharecast News) - AstraZeneca announced positive high-level results from a phase three trial demonstrating significant advancements in the treatment of limited-stage small cell lung cancer (LS-SCLC) on Friday.

Read more
4 Apr 2024 13:09

UK shareholder meetings calendar - next 7 days

Friday 5 April 
Faron Pharmaceuticals LtdAGM
VPC Specialty Lending Investments PLCGM re capital return via B share scheme
Monday 8 April 
Premier African Minerals LtdAGM
Tuesday 9 April 
Ethernity Networks LtdEGM re board appointments and option grants
Wednesday 10 April 
Valereum PLCAGM
Wincanton PLCGM re takeover by GXO Logistics Inc
Thursday 11 April 
AstraZeneca PLCAGM
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
3 Apr 2024 22:01

Biden, Senator Bernie Sanders push companies to cut cost of asthma inhalers, prescription drugs

WASHINGTON, April 3 (Reuters) - President Joe Biden hosted a White House event with U.S. Senator Bernie Sanders on Wednesday to tout their fight against high prescription drug prices and push companies to cut the cost of inhalers for asthma sufferers.

Read more
3 Apr 2024 17:22

UK's FTSE 100 pressured by stronger pound; miners climb

FTSE 100 flat, FTSE 250 up 0.2%

*

Read more
3 Apr 2024 11:02

CORRECT: AstraZeneca, Daiichi make US progress with licence approvals

(Correcting the description of extravascular haemolysis' effects on patients with paroxysmal nocturnal haemoglobinuria)

Read more
2 Apr 2024 15:22

London close: Stocks turn red on return from Easter break

(Sharecast News) - UK stocks experienced a downturn by the end of trading on Tuesday, as investors resumed activity following the extended weekend, with initial gains reversed by the close ahead of a week marked by a number of key economic data releases.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.